Literature DB >> 3536093

The role of host lymphocytes and host macrophages in antitumor reactions after injection of sensitized lymphocytes and tumor target cells into naive mice.

H F Dullens, W Vuist, M Van der Maas, W Den Otter.   

Abstract

DBA/2 mice were immunized i.p. against syngeneic SL2 lymphosarcoma cells. At various days after the last immunization peritoneal and spleen lymphocytes were collected. The lymphocyte suspensions were enriched for T-cells by nylon wool filtration. The peritoneal T-cells from immunized mice (a) expressed direct specific antitumor cytotoxicity in vitro, (b) induced macrophage cytotoxicity in vitro, and (c) exerted tumor neutralization measured in a Winn-type assay. Spleen T-cells from these immunized mice (a) expressed no direct specific antitumor cytotoxicity in vitro, (b) only induced moderate macrophage cytotoxicity in vitro, but (c) exerted tumor neutralization in a Winn assay. For effective tumor neutralization in vivo effector target cell ratios of 1000:1 were required. When the effector/target ratio of 1000:1 was maintained but the absolute numbers of effector and target cells were lowered from 10(6) to 10(5) lymphocytes and 10(3) to 10(2) target cells respectively, no tumor neutralization was obtained. The major effect of the sensitized-transferred T-lymphocytes seemed to be the induction of cytotoxic macrophages in the (naive) recipient mice, as the peritoneal macrophages collected from the recipient mice 7 days after i.p. injection of a mixture of sensitized T-cells and tumor cells were cytotoxic. Purified peritoneal T-lymphocytes collected from these recipient mice were able to induce macrophage cytotoxicity in vitro but expressed no cytotoxic T-cell activity. In conclusion, our results show that in the tumor system used, tumor neutralization after transfer of sensitized lymphocytes is not dependent on the presence of cytotoxic T-lymphocytes. Lymphocytes with the strongest potency to render macrophages cytotoxic (in vitro and in vivo) also induce the best tumor neutralization in vivo, suggesting an important role for host macrophages as antitumor effector cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3536093     DOI: 10.1007/BF00199816

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  30 in total

1.  T cell-mediated immunity to oncornavirus-induced tumors. I. Ly phenotype of precursor and effector cytolytic T lymphocytes.

Authors:  J C Leclerc; H Cantor
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

2.  Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.

Authors:  H Nakajima; H Fujiwara; Y Takai; Y Izumi; S Sano; T Tsuchida; T Hamaoka
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

3.  Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations.

Authors:  M Rosenstein; T J Eberlein; S A Rosenberg
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

4.  The immunological basis of tumor rejection: the absolute dependence of the effector arm on sensitized T cells after chemoimmunotherapy of a murine sarcoma.

Authors:  R Evans; T Duffy
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

5.  Lymphocyte-induced macrophage cytotoxicity. III. Induction of specific macrophage cytotoxicity is independent of lipopolysaccharide.

Authors:  R A de Weger; H van Loveren; J W de Groot; R Rangarajan; W den Otter
Journal:  Immunobiology       Date:  1986-04       Impact factor: 3.144

6.  Adoptive immunotherapy of intracerebral murine lymphomas: role of different lymphoid populations.

Authors:  L Romani; B Nardelli; R Bianchi; P Puccetti; M Mage; M C Fioretti
Journal:  Int J Cancer       Date:  1985-05-15       Impact factor: 7.396

7.  The induction of lymphocytes with the capacity to render macrophages cytotoxic in an allogeneic murine system.

Authors:  R A De Weger; E Pels; W Den Otter
Journal:  Immunology       Date:  1982-11       Impact factor: 7.397

8.  Distribution of tumor-sensitized cells during the induction of permanent tumor regression by chemoimmunotherapy: the use of glucose phosphate isomerase as a marker.

Authors:  R Evans; T M Duffy
Journal:  Int J Cancer       Date:  1984-10-15       Impact factor: 7.396

9.  The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.

Authors:  H Fujiwara; M Fukuzawa; T Yoshioka; H Nakajima; T Hamaoka
Journal:  J Immunol       Date:  1984-09       Impact factor: 5.422

10.  Activation of macrophages by lymphokines from T-cell clones: evidence for different macrophage-activating factors.

Authors:  D Gemsa; C Kubelka; K M Debatin; P H Krammer
Journal:  Mol Immunol       Date:  1984-12       Impact factor: 4.407

View more
  4 in total

1.  Augmented induction of antitumor cells in vivo by cyclophosphamide fails to benefit antitumor resistance of the host.

Authors:  K Ryoyama; C Ryoyama
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Characterization of variant and parental-cross-protective immunity to immunogenic variants of a murine fibrosarcoma using the local adoptive transfer assay.

Authors:  W Simcik; T L Sheu; S J LeGrue
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Production of specific macrophage-arming factor precedes cytotoxic T lymphocyte activity in vivo during tumor rejection.

Authors:  H F Dullens; R A De Weger; M Van der Maas; P J Den Besten; R J Vandebriel; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  The absence of delayed-type hypersensitivity reactivity in a syngeneic murine tumour system.

Authors:  G Los; R A De Weger; R M Moberts; H Van Loveren; R J Sakkers; W Den Otter
Journal:  Immunology       Date:  1987-09       Impact factor: 7.397

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.